{
  "id": 5125219,
  "title": "CBER official overruled review team's rejection of new Replimune melanoma drug",
  "url": "https://urgent.news/2026/09/02/cber-official-overruled-review-teams-rejection-of-new-replimune",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T16:02:32.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/cber-official-overruled-review-teams-rejection-of-new-replimune-melanoma-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Asha Das, director of the FDA biologics center's office of clinical evaluation, overruled the agency's review team in granting an accelerated approval to Replimune's melanoma treatment Tudriqev in early August, new documents from the agency ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}